Emphasis on biotechnology and commercial aspects - composition, activity, nomenclature, companies involved and relationships, manufacturing methods, patents/technology transfer, regulatory history/status, approved indications, market size/share, controversial aspects, etc.
Over 500 product monographs (spanning 1,250 pages); up-to-date into July 1, 2006; includes all:
recombinant and other proteins
antibodies - monoclonal, radioimmune conjugates
vaccines
enzymes and toxins
blood products - human and animal-derived
cultured cell and tissue products
and other products, e.g., vaccine adjuvants, antisense drugs
Coverage - Includes all biopharmaceuticals approved in the U.S. and European Union, those with filings expected in 2006-7, formerly approved, and with applications denied or withdrawn
Indexes - provide unprecedented access to biopharmaceutical products and companies; over 170 pages; 26,500+ index entries (ave. >50/product)
Products/Active Agents (nomenclature), Class, Biological, Chemical, Medical, Market Size/Total Sales, Recombinant Expression/Host System, Regulatory/Status and Approval Date Indexes
Company, Company Role, Country, State, and Marketing Territory Indexes
New! Bonus Sections - Reviews and analyses of products, FDA approvals and biogenerics (follow-on proteins, biosimilars, etc.)
2 volumes, 1,480 pages - 8.5" x 11, hard cover bound
|
